|
Vestn Khir Im I I Grek.
2001;160(4):32-8. |
Clinico-experimental basis for regional and
systemic administration of thiopoietins in liver
cirrhosis. Report I.
[Article in Russian].
Borisov AE, Kozhemiakin
LA, Antushevich AE, Ketlinskaia
OS, Kashenko VA, Chepur SV,
Katsalukha VV, Vasiukova
EL, Novichenkov AO, Motushchuk
IE.
The authors present results of studying the effectiveness of a new class of
medicines--preparations of the group "Glutoxim" (Molixan,
Redoxell, Bikvolit, Liglutin) obtained on the model of experimental cirrhosis
of the liver in 76 white rats caused by dimethylnitrosamin,
and describe their first experience with using thiopoietins
in 24 patients with cirrhosis of the liver in a surgical clinic. It was found
that three weeks of treatment with Molixan and Bikvolit gave a significant hepatoprotecting
effect (less amount of the connective tissue, reduction of the dystrophic
processes in hepatocytes). A positive effect of Redoxell was shown in longer time of treatment. When used
in clinic therapy with thiopoietins was followed by
correction of the T-cell link of immunity in most patients. One of the most
important results of treatment with medicines of the group of thiopoietins was a substantial improvement of the quality
of life of the patients.